Related Experiment Video
Updated: Jan 28, 2026

Human Fear Conditioning Conducted in Full Immersion 3-Dimensional Virtual Reality
Published on: August 9, 2010
Dawn of Theranostics in Myanmar (Dream, Reality, and Constraint)
Kyin Myint1, Tin Maung Thein1, Thiri Kyi Phyu2
1PERFECT Myanmar Molecular Imaging and Therapy center (PERFECT MMITC), No (122/124), 15th street (Middle block), Ward 7, Lanmadaw Township, 11131 Yangon, Myanmar.
Abstract:
Prostate cancer is third common malignancy in men of old age (average 65 years) in Myanmar. Currently, serum PSA and bone scan are the markers of choice. Because of the evidence-based, promising success of 68Ga-PSMA PET-CT and 177Lu-PSMA theranostics in prostate cancer worldwide, 99mTc-PSMA SPECT-CT imaging and 177Lu-PSMA therapy has launched as a stepping-stone of theranostics in Myanmar with the available facilities. Twelve cases of prostate cancer patients were imaged with 600 MBq of 99mTc-PSMA I+S SPECT-CT. Four metastatic castration resistant prostate cancer (MCRPC) patients with abnormal result were treated with 177Lu-PSMA. The protocol consists of 6-8 GBq of 177Lu-PSMA, three successive doses at interval of 4-6 weeks. Post-therapy SPECT-CT imaging was done. All treated patients were improved by free of bone pain, and fall/rise in serum PSA level. Two patients with extensive skeletal metastases succumbed to complications. The results are well documented and present at the multidisciplinary conferences for clinical awareness. Theranostics in prostate cancer with available facilities is an additional boon to our health care professionals to upgrade cancer management in Myanmar. This paper provides the technology with cost effectiveness and benefit to prostate cancer patients of Myanmar.
Related Concept Videos
Dreaming
Lucid Dreaming
Studies have shown...
Constraints and Statical Determinacy
Obedience
Cognitive Dissonance
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...

